by Wiggin and Dana LLP | Sep 15, 2019
Biotechnology Disputes with Investigators over Publication of Clinical Trial Data Below are just two examples of the ongoing conflict between the research community's need to publish and the pharmaceutical/biotechnology industry's need to maintain the...
by Wiggin and Dana LLP | Sep 15, 2019
Intellectual Property Rights and Licenses May Determine the Future of U.S. Stem Cell Research Although the recent debate on the use of human embryonic stem cells for research purposes centers on the ethical dilemma, the true extent of future stem cell research that...
by Wiggin and Dana LLP | Sep 15, 2019
Alternatives to Venture Capital Financing Recently, venture capital firms have become more careful with investments, frequently choosing to focus on their existing portfolio companies. As a result, cash constrained biotech companies with no public market must consider...
by Wiggin and Dana LLP | Sep 15, 2019
Patent Term Extensions Extend Revenues Even with recent steps taken by the FDA to fast track the new drug application and approval process, the period between application and approval remains lengthy. As a result, patent holders may be deprived of the full benefit of...
by Wiggin and Dana LLP | Sep 15, 2019
The CREATE Act: Protecting Patentable Inventions that Arise from Collaborative Research The Cooperative Research and Technology Enhancement (CREATE) Act of 2004 was signed into law by President Bush on December 10, 2004. The Act amends 35 U.S.C. §103(c) of the...
